

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : El-Naggar et al.

Examiner: B. Kwon

Appl. No. : 09/943,048

Art Unit: 1614

Filed : August 30, 2001

For : Treatment of Inflammatory, Cancer, and Thrombosis Disorders

FAX RECEIVED

CANCELLED JUN 27 2003

PETITIONS OFFICE

FAX RECEIVED

JUN 30 2003

PETITIONS OFFICE

Commissioner of Patents
And Trademarks
Washington, D.C. 20231

Sir:

This Amendment responds to the Office Action mailed April 10, 2002. A request for three months extension of time accompanies this Amendment. Please amend the application as follows:

Response to Restriction Requirement

Applicants affirm, with traverse, election of group III (Claim 4) in response to a restriction requirement.

AmendmentIN THE CLAIMS:

Please amend claims 1 and 5 as follows:

- B1
1. (Amended) A method of treating inflammatory disorders in a mammal comprising administering to said mammal a combination of: (i) a standard therapeutic dose of a COX2 inhibitor selected from the group consisting of [(i)] celecoxib [(CelebrexR) [A,]] and rofecoxib [(VioxxR) [B], and other specific COX2 inhibitors [C]], (ii) low dose aspirin in the amount of [C] 70-85 mg[C], and (iii) antioxidant flavanoids, flavonoids or isoflavones.
 5. (Amended) The method of claim 1, wherein the [COX2 inhibitors is compound [A], compound [B] or compound [C] and] low dose aspirin [of 70-85 mg] is in an enteric coated formulation. [This preferred enteric-coated formulation should allow for improved efficacy and safety.]
- B2